Polarean Imaging CEO Dr. Christopher von Jako joined Steve Darling from Proactive to share exciting developments in the company’s financial and operational progress during the first half of 2024. Revenues soared from $100,000 to $1.1 million, reflecting the company’s growing success in commercializing its pulmonary functional xenon MRI systems. Dr. von Jako emphasized Polarean's dedication to cost management, with operating expenses reduced from $7.7 million to $4.6 million. The company also bolstered its financial position through a successful £10 million fundraising round. Expansion efforts are underway, with strategic hires and a notable order from the University of Alabama at Birmingham. In a significant move to broaden its market reach, Polarean submitted an FDA supplement aimed at lowering the minimum age for their technology's use from 12 to 6, potentially opening access to an additional one million children. Dr. von Jako expressed optimism about the company's future, raising revenue guidance for the full year and announcing plans for a virtual investor day in October. #proactiveinvetors #polareanimagingplc #aim #polx #MedicalTechnology #XenonMRI #HealthcareInnovation #CEOInterview #FinancialResults #FDAApproval #HealthcareInvesting #PulmonaryHealth #MedicalImaging#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews